Dashboard/VKTX/dapiglutide/event

Conf.Conference Data

Dapiglutide Oral Phase 1b Cardiometabolic Data — ADA 2026

VKTX·dapiglutide·Obesity·

Phase 3

current best date

MAY–MAY

2026

WINDOW30 days

Takeaway

Phase 1b cardiometabolic biomarker data for oral dapiglutide at ADA 2026. Closest oral GLP-1 comparator in development: Lilly’s orforglipron. Watch: weight change, A1c, fasting glucose, GI tolerability at oral exposure levels.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~58%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAdual GLP-1 / GIP receptor agonist

dapiglutide (VK2735) is Viking Therapeutics' dual GLP-1/GIP receptor agonist in development for weight management in adults with obesity. The drug mimics two gut hormones — GLP-1 and GIP — that regulate appetite and blood sugar, prompting the brain to reduce food intake and the body to use energy more efficiently. Viking is evaluating both a once-weekly subcutaneous injection and a daily oral formulation, targeting a competitive profile against semaglutide and tirzepatide in the Phase 3 VENTURE trial.

Indication

Obesity / GLP-1

Obesity

MeSH · D009765

No primer in glossary yet.

Source signal

This event was extracted from a primary disclosure. The full chain of citations is in the disclosure trail below.

Glossary · what this readout is measuring

2 terms detected in the takeaway

GLP-1target
Glucagon-like peptide-1
Gut hormone that triggers insulin release and slows gastric emptying. GLP-1 receptor agonists (semaglutide, tirzepatide) drive weight loss and glycemic control.
A1cendpoint
Hemoglobin A1c
Three-month average blood glucose. Standard primary endpoint in diabetes trials; absolute reduction of ≥0.5% is meaningful.

Competitive landscape

2 peers in Obesity / GLP-1 · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Phase	Next catalyst
RM-718	RYTM	peptide	weekly MC4R agonist (next-gen)		READOUT · Oct 26
IMCIVREEsetmelanotide	RYTM	peptide	MC4R agonist		PDUFA · Aug 26

Prior VKTX reactions to Conf. events

1 historical event · base rate, not prediction

Median 1W move

+8.2%

Median 1M move

+4.3%

Positive outcomes

1/ 1

100%

Negative outcomes

0/ 1

Date	Headline	Outcome	1W	1M	6M
Nov 2025	dapiglutide — ASH Late-Breaker — Updated Survival	positive	+8.2%	+4.3%	+6.6%

Historical VKTX stock reaction to past Conf. catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 100%.

Disclosure trail

1 observation · sorted by confidence

Feb 14, 2026·2mo agopinned · highest confidence
HIGH conf8-K
top claim
MAY–MAY2026
WINDOW
“Phase 1b cardiometabolic biomarker data for the oral formulation of dapiglutide will be presented at the American Diabetes Association Scientific Sessions (May 30 – June 2, 2026).”
conf 89%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.